|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression of the oncogene hepatocyte growth factor receptor (MET) and phosphorylation of the MET protein have been associated with both primary and acquired resistance to tyrosine kinase inhibitors (TKIs) used in therapy targeting the epidermal growth factor receptor (EGFR) in patients with non-small cell lung cancers (NSCLCs).
|
25522678 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ERBB2 and MET alterations include both activating mutations and gene amplifications, detection of which relies on molecular methods with a minimal role for IHC in NSCLC.
|
30188361 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MET copy number was examined in 28 NSCLC and 4 human bronchial epithelial cell lines (HBEC) and 100 primary tumors using quantitative real-time PCR.
|
19117057 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although multiple MET tyrosine kinase inhibitors (TKIs) are being actively developed for MET-driven NSCLC, the mechanisms of acquired resistance to MET-TKIs have not been well elucidated.
|
30309221 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ALK and ROS1 are prognostic and predictive tumor markers in non-small cell lung carcinoma (NSCLC), which are more often found in lung adenocarcinomas as with other oncogenes such as EGFR, KRAS, or C-MET.
|
30327151 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MET gene copy number (GCN) status was evaluated using fluorescent in situ hybridization (FISH) and MET protein expression using immunohistochemistry (IHC) in tissue microarray sections from a retrospective cohort of 300 surgically resected NSCLCs including 93 cases with nodal metastases.
|
26395411 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A significant correlation was found between the plasma soluble c-Met levels and tissue c-Met protein expression in patients with advanced non-small-cell lung cancer.
|
27461774 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The clinical resistance of non-small cell lung cancer (NSCLC) to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been linked to EGFR T790M resistance mutations or MET amplifications.
|
28521430 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
|
24688052 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MET amplification or MET exon 14 skipping site mutation can be treated with crizotinib in non-small cell lung cancer patients.
|
30885356 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated remarkable efficacy in ROS1-rearranged NSCLC.
|
29517860 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings suggest that cigarette smoke augments oncogene addiction to c-MET in NSCLC cells and that MET inhibitors may show clinical benefits for lung cancer patients with a smoking history.
|
29570930 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MET inhibitors have the potential to benefit subsets of NSCLC patients with specific genetic alterations.
|
29621416 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These results demonstrated how the mutated residues tune the crizotinib response and may assist kinase inhibitor development especially for ALK G1202R, analogous to the ROS1 G2302R and MET G1163R mutations that are also resistant to crizotinib treatment in NSCLC.
|
31388026 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines.
|
23527257 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Non-small cell lung cancer (NSCLC) sensitive to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) often acquires resistance through secondary EGFR mutations, including the T790M mutation, aberrant c-Met receptor activity, or both.
|
28469968 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, this meta-analysis indicates that high MET CNG is an adverse prognostic factor in patients with NSCLC.
|
29805710 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
c-MET H-score ≥20 is a positive prognostic biomarker for OS in early stage NSCLC.
|
31200831 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The mesenchymal-to-epithelial transition (MET) gene is altered and becomes a driver mutation in up to 5% of non-small-cell lung cancer (NSCLC).
|
30762593 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings support an intimate relationship between the EGFR and MET signaling pathways in NSCLC, and they suggest that combination treatment with MET and EGFR kinase inhibitors may be beneficial in MET-amplified NSCLC by reducing selection for drug resistant clones.
|
20124471 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
But it remains uncertain whether MET amplification could be related to primary TKI resistance in NSCLC because of limited data.
|
22052229 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
<i>ROS1</i> rearrangements define a distinct molecular subset of non-small-cell lung cancer (NSCLC), which can be treated effectively with crizotinib, a tyrosine kinase inhibitor (TKI) targeting <i>ROS1/MET/ALK</i> rearrangements.
|
30940295 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We sought to demonstrate the activity of INC-280 on select NSCLC cell lines both as a single agent and in combination with erlotinib using exogenous HGF to simulate MET up-regulation.
|
28038979 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although relationship between MET copy number gain and poor prognosis has been suggested in surgically resected non-small cell lung cancer, the clinical significance of MET copy number gain and protein overexpression in patients with advanced unresectable tumor is unclear.
|
31329925 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
One of these RTKs, c-ros oncogene 1, receptor tyrosine kinase (ROS1), has been identified as a driver mutation in NSCLC, because its inhibition by crizotinib, an anaplastic lymphoma receptor tyrosine kinase (ALK)/met proto-oncogene hepatocyte growth factor receptor (MET)/ROS1 inhibitor, led to significant tumor shrinkage in ROS1-rearranged NSCLC.
|
23400546 |
2013 |